Governments in Europe and Japan Have Acknowledged a Valuable Role for Appropriate Offlabel Use of Cancer Therapies, but Tough Reimbursement Restrictions Severely Limit Physicians' Prescribing Freedoms.
Business Wire › December 19, 2006
Linked as:
Extract
Governments in Europe and Japan Have Acknowledged a Valuable Role for Appropriate Offlabel Use of Cancer Therapies, but Tough Reimbursement Restrictions Severely Limit Physicians' Prescribing Freedoms.
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47286) has announced the addition of Cancer Therapies Face Increasing Reimbursement Pressures in Europe and Japan to their offering....
See the full content of this document
Sponsored links
